1.Greenberg, PE, Kessler, RC, Birnbaum, HG et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465–1475.
2.Kessler, RC, Berglund, P, Demler, O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105.
3.Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Second Edition. Arlington, VA: American Psychiatric Association; 2000;vii–87.
4.Clinical Practice Guideline Number 5: Depression in Primary Care, 2. Treatment of Major Depression. Rockville, Md: Agency for Health Care and Policy Research: US Dept of Health and Human Services; 1993. AHCPR publication 93–0551.
5.Mueller, TI, Leon, AC. Recovery, chronicity, and levels of psychopathology in major depression. Psychiatr Clin North Am. 1996;19:85–102.
6.Keller, MB, Harrison, W, Fawcett, JA et al. , Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. Psychopharmacol Bull. 1995;31:205–212.
7.Trivedi, MH, Rush, AJ, Wisniewski, SR et al. , Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
8.Frank, E, Karp, JF, Rush, AJ. Efficacy of treatments for major depression. Psychopharmacol Bull. 1993;29:457–475.
9.Fava, M, Davidson, KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19:179–200.
10.Miller, IW, Keitner, GI, Schatzberg, AF et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertra-line or imipramine. J Clin Psychiatry. 1998;59:608–619.
11.Judd, LL, Paulus, MP, Wells, KB, Rapaport, MH. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry. 1996;153:1411–1417.
12.Judd, LL, Akiskal, HS, Zeller, PJ et al. , Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry. 2000;57:375–380.
13.Judd, LL, Akiskal, HS, Maser, JD et al. , Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50:97–108.
14.Judd, LL, Paulus, MJ, Schettler, PJ et al. , Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000;157:1501–1504.
15.Van Londen, L, Molenaar, RP, Goekoop, JG, Zwinderman, AH, Rooijmans, HG. Three- to 5-year prospective follow-up of outcome in major depression. Psychol Med. 1998;28:731–735.
16.Mueller, TI, Leon, AC, Keller, MB et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156:1000–1006.
17.Diagnostic and Statistical Manual of Mental Disorders. 4th ed text rev. Washington, DC: American Psychiatric Association; 2000.
18.Kessler, RC, McGonagle, KA, Zhao, S et al. , Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19.
19.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
20.Kessler, RC, Berglund, P, Demler, O, Jin, R, Walters, EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602.
21.Keller, MB, Lavori, PW, Endicott, J, Coryell, W, Klerman, GL. “Double depression”: two-year follow-up. Am J Psychiatry. 1983;140:689–694.
22.Keller, MB, Hirschfeld, RM, Hanks, D. Double depression: a distinctive subtype of unipolar depression. J Affect Disord. 1997;45:65–73.
23.Simon, GE. Long-term prognosis of depression in primary care. Bull World Health Organ. 2000;78:439–445.
24.Trivedi, MH. Treatment-resistant depression: new therapies on the horizon. Ann Clin Psychiatry. 2003;15:59–70.
25.Solomon, DA, Leon, AC, Mueller, TI et al. , Tachyphylaxis in unipolar major depressive disorder. J Clin Psychiatry. 2005;66:283–290.
26.Thase, ME. New approaches to managing difficult-to-treat depressions. J Clin Psychiatry. 2003;64(Suppl 1):3–4.
27.Quitkin, FM, McGrath, PJ, Stewart, JW et al. Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. J Clin Psychiatry. 2005;66:670–676.
28.Schatzberg, AF, Rush, AJ, Arnow, BA et al. , Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry. 2005;62:513–520.
29.Zajecka, JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry. 2000;61(Suppl 2):20–25.
30.Thase, ME, Rush, AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(suppl 13):23–29.
31.Cadieux, RJ. Practical management of treatment-resistant depression. Am Fam Physician. 1998;58:2059–2062.
32.Nurnberg, HG, Thompson, PM, Hensley, PL. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry. 1999;60:574–579.
33.Kroenke, K, West, SL, Swindle, R et al. , Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286:2947–2955.
34.Fredman, SJ, Fava, M, Kienke, AS, White, CN, Nierenberg, AA, Rosenbaum, JF. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current “next-step” practices. J Clin Psychiatry. 2000;61:403–408.
35.Nelson, JC. Augmentation strategies in depression 2000. J Clin Psychiatry. 2000;61(Suppl 2):13–19.
36.Nelson, JC. Overcoming treatment resistance in depression. J Clin Psychiatry. 1998;59:13–19.
37.Thase, ME. What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry. 2002;63:95–103.
38.Trivedi, MH, Kleiber, BA. Algorithm for the treatment of chronic depression. J Clin Psychiatry. 2001;62:22–29.
39.Trivedi, MH. Using treatment algorithms to bring patients to remission. J Clin Psychiatry. 2003;64(Suppl 2):8–13.
40.Crismon, ML, Trivedi, M, Pigott, TA et al. , The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry. 1999;60:142–156.
41.Katon, W, Von Korff, M, Lin, E et al. , Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA. 1995;273:1026–1031.
42.Rush, AJ, Crismon, ML, Toprac, MG et al. , Implementing guidelines and systems of care: experiences with the Texas Medication Algorithm Project (TMAP). J Pract Psychiatry Behav Health. 1999;5:75–86.
43.Rush, AJ, Crismon, ML, Kashner, TM et al. , Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry. 2003;64:357–369.
44.Trivedi, MH, Rush, AJ, Crismon, ML et al. , Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry. 2004;61:669–680.
45.Biggs, MM, Shores-Wilson, K, Rush, AJ et al. , A comparison of alternative assessments of depressive symptom severity: a pilot study. Psychiatry Res. 2000;96:269–279.
46.Trivedi, MH, Rush, AJ, Gaynes, BN et al. , Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D Measurement-Based Care. Neuropsychopharmacology. 2007. Apr 4 [Epub ahead of print]
47.Rush, AJ, Fava, M, Wisniewski, SR et al. , Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119–142.
48.Clinical Practice Guideline Number 5: Depression in Primary Care, 1: Detection and Diagnosis. Rockville, Md: Agency for Health Care and Policy Research, US Dept of Health and Human Services; 1993. AHCPR publication 93–0550.
49.Trivedi, MH, Claassen, CA, Grannemann, BD et al. , Assessing physicians' use of treatment algorithms: Project IM PACTS study design and rationale. Contemp Clin Trials. 2007;28:192–212.
50.Gilbert, DA, Altshuler, KZ, Rago, WV et al. , Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry. 1998;59:345–351.
51.Rush, AJ, Rago, WV, Crismon, ML et al. , Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. J Clin Psychiatry. 1999;60:284–291.
52.Glasgow, RE, Bull, SS, Piette, JD, Steiner, JF. Interactive behavior change technology. A partial solution to the competing demands of primary care. Am J Prev Med. 2004;27:80–87.
53.Trivedi, MH, Kern, JK, Baker, SM, Altshuler, KZ. Computerizing medication algorithms and decision support systems for major psychiatric disorders. J Psychiatr Pract. 2000;6:237–246.
54.Trivedi, MH, Kern, JK, Grannemann, BD, Altshuler, KZ, Sunderajan, P. A computerized clinical decision support system as a means of implementing depression guidelines. Psychiatr Serv. 2004;55:879–885.
55.Sequenced Treatment Alternatives to Relieve Depression (Star*D) study. National Institute of Mental Health and University of Pittsburgh Epidemiology Data Center. Available at: http://www.edc.pitt.edu/stard/ Accessed March 28, 2007.
56.Kupfer, DJ. Long-term treatment of depression. J Clin Psychiatry. 1991;52(suppl):28–34.
57.Streja, DA, Hui, RL, Streja, E, McCombs, JS. Selective contracting and patient outcomes: a case study of formulary restrictions for selective serotonin reup-take inhibitor antidepressants. Am J Manag Care. 1999;5:1133–42.
58.Russell, JM, Berndt, ER, Miceli, R, Colucci, S, Grudzinski, AN. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. Am J Manag Care. 1999;5:597–606.
59.Melfi, CA, Chawla, AJ, Croghan, TW, Hanna, MP, Kennedy, S, Sredl, K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55:1128–1132.
60.Lin, EH, Von Korff, M, Katon, W et al. , The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33:67–74.